Kantar Health Blog

  • Debbie Warner
    Opdivo (nivolumab, Bristol-Myers Squibb) is approved for the treatment of patients with squamous cell non-small cell lung cancer (NSCLC) who have relapsed on platinum-based chemotherapy. Based on the clinical trial that served as the basis for approval, Opdivo did not stratify response rates based on PD-L1 levels, and the approved label does not have a biomarker requirement.
    Continue Reading > | Go comment! | Share
  • Wear it … but only if it fits

    by Mark Sales | Jul 17, 2015
    Mark Sales
    Being on the cutting edge of technology is a great thing. It’s an exciting thing. But remember that the end user experience is the most important part of developing any product or app.
    Continue Reading > | Go comment! | Share
  • Debbie Warner
    Value was an overarching theme at ASCO 2015 and has been a topic of ongoing focus, as have been the burgeoning pipeline of immunotherapy agents, with the recently launched PD-1 inhibitors, Opdivo® (nivolumab, Bristol Myers Squibb) and Keytruda® (pembrolizumab, Merck), being the highlights of ASCO 2015. Presenter Leonard Saltz, M.D. of Memorial Sloan Kettering praised the clinical value of an Opdivo + Keytruda combination as being “truly, truly remarkable,” but he added that with the combination costing nearly $300,000 (if continued for 11 months) “these drugs cost too much –unsustainable.” While Dr. Saltz is an unabashed critic of cancer drug prices, $300,000 would give most people pause.
    Continue Reading > | Go comment! | Share
  • Mark Sales
    If you are still focused on whether a customer experience program will bring value to your organization, you are missing the point.
    Continue Reading > | Go comment! | Share
  • Crowd surfing: Competition in myeloma continues to rage on

    by Stephanie Hawthorne | Jun 2, 2015
    Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- The number of agents available to treat relapsed/refractory myeloma has expanded rapidly over the past three years, with the launch of next-generation proteasome inhibitor Kyprolis® (carfilzomib, Onyx /Amgen, accelerated FDA approval July 2012) and the next-generation immunomodulator Pomalyst® (pomalidomide, Celgene, FDA approved February 2013) as monotherapies, and the HDAC inhibitor Farydak® (panobinostat, Novartis, accelerated FDA approval February 2015) for use in combination with bortezomib + dexamethasone (VelDex). These three agents add to the long-established standards of care, Velcade® (bortezomib, Millennium/Takeda) and Revlimid® (lenalidomide, Celgene), which are used in both newly diagnosed and relapsed/refractory patients.
    Continue Reading > | Go comment! | Share